Asciminib
Asciminib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Philadelphia Chromosome-Positive、Acute Lymphoblastic Leukemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
22 项
全球在招研究
1 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- M.D. Anderson Cancer Center
- Novartis Pharmaceuticals
- Marlise Luskin, MD
- City of Hope Medical Center
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Duke University
- Korean Society of Hematology
- Medical College of Wisconsin
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、德国、South Korea、法国、Greece、Hungary、意大利、日本、荷兰、Poland、Russia
正在招募患者的 Asciminib 研究
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
不适用招募中中国NCT07375355A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
不适用招募中美国NCT07091019A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
不适用招募中德国NCT07549516Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
II 期招募中美国NCT06629584Asciminib RMP Study
不适用招募中South KoreaNCT05943522Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
I 期 / II 期招募中美国NCT06308588ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
I 期招募中美国NCT03595917Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
I 期招募中美国NCT07040982Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
II 期招募中法国NCT06514534Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
I 期 / II 期招募中美国中国法国德国NCT04925479Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
I 期 / II 期招募中澳大利亚IsraelSouth Korea中国台湾NCT07387926Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
II 期招募中美国NCT06236724PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
II 期招募中西班牙NCT06409936Asciminib in HER2+ Breast Cancer Brain Metastases
I 期 / II 期招募中美国NCT07136428A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
II 期招募中South KoreaNCT06368414RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
不适用招募中Saudi ArabiaNCT06684964Asciminib Roll-over Study
IV 期招募中美国Argentina奥地利BrazilNCT04877522Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
II 期招募中美国NCT04838041Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
II 期招募中美国NCT06817720Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
II 期招募中美国澳大利亚Brazil加拿大NCT07354074Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
I 期招募中美国NCT07250087Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
II 期招募中中国NCT06985485
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。